Septerna is a pre-revenue biotech with elite cash conversion (FCF margin 33%) and strong analyst support, but a consistent earnings miss streak and high short interest of 11% create meaningful downside risk that outweighs the 10.5% upside at current prices.
Thesis pillars
- Analyst Conviction Price Target Upside→Stable
- Fcf Positive Pre Revenue Biotech→Stable
- High Implied Volatility Options Risk→Stable
- +1 more pillar — see the Why tab for full reasoning
Septerna, Inc. (SEPN) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $34.00: Risk below floor (1.8 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: High short interest: 12%; Elevated put/call ratio: 15.83; Below-average business quality.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule... Read more
Sell if holding. Engine safety override at $34.00: Risk below floor (1.8 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: High short interest: 12%; Elevated put/call ratio: 15.83; Below-average business quality. Chart setup: RSI 50 mid-range, Bollinger mid-band. Score 4.7/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news boost analyst 0.50, earnings proximity 38d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: speculative.
Recent developments
updated 2026-07-06Recent Developments — Septerna, Inc.
Latest news
- NEWS Guggenheim Maintains Buy on Septerna, Lowers Price Target to $45 — benzinga Jul 1, 2026 neutral
- NEWS HC Wainwright & Co. Reiterates Buy on Septerna, Maintains $40 Price Target — benzinga Jul 1, 2026 positive
- NEWS Truist Securities Maintains Buy on Septerna, Raises Price Target to $43 — benzinga Jul 1, 2026 positive
- NEWS Raymond James Maintains Strong Buy on Septerna, Raises Price Target to $53 — benzinga Jun 8, 2026 positive
- NEWS Septerna Announces First Detailed Preclinical Characterization Of SEP-479 Accepted For Oral Presentation At ENDO 2026 — benzinga Jun 8, 2026 positive
Generated 2026-07-06T06:00:35Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Volatile — 7.4% daily ATR makes tight stops impractical. Position-size conservatively.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $34.00: Risk below floor (1.8 < 3.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: High short interest: 12%; Elevated put/call ratio: 15.83; Below-average business quality. Chart setup: RSI 50 mid-range, Bollinger mid-band. Prior stop was $31.62. Score 4.7/10, moderate confidence.
Take-profit target: $39.15 (+15.1% upside). Prior stop was $31.62. Stop-loss: $31.62.
Risk below floor (1.8 < 3.0); Value-trap signals (2/5): High leverage (D/E 3.6), Material insider selling (3 sells, 15.11% of cap).
Septerna, Inc. trades at a P/E of N/A (forward -12.8). TrendMatrix value score: 4.5/10. Verdict: Sell.
15 analysts cover SEPN with a consensus score of 4.2/5. Average price target: $45.
What does Septerna, Inc. do?Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral...
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.